
Oncology
FDA Expands Anktiva Plus BCG Approval to Papillary-Only Bladder Cancer
The FDA expanded Anktiva plus BCG to adults with BCG-unresponsive, high-grade papillary-only non–muscle-invasive bladder cancer, adding a bladder-preserving option for this underserved group.
Dr. Abu Bakar · October 22, 2026 · 7 min
